Immunomodulatory therapies have advanced to clinical trials over the past decade for the treatment of a range of diseases and disorders, from cancer to diabetes to transplant rejection. However, the efficacy of these therapies remains limited, as challenges associated with off-target drug toxicity, poorly controlled drug pharmacokinetics, and an incomplete understanding of real-time therapy responses prevent effective therapeutic windows from being realized. Here, we highlight some of our work on the design, fabrication, and characterization of biomaterial-based delivery technologies for the controlled delivery of immunotherapies and for the non-invasive monitoring of their associated immune responses for the treatment of cancer and autoimmune disease.
Megan Goldberg, m.goldberg@wustl.edu, 314-747-6978
Natalie Artzi, MD, PhD
Associate Professor of Medicine at Harvard Medical School
Principal Research Scientist at MIT
Associate Faculty at the Wyss Institute for Biologically Inspired Engineering
No recent activity